The aim of this work was to compare mean concentrations of gonadotropins in serum and fluid from malignant and benign ovarian tumors. We enrolled 126 patients diagnosed with malignant epithelial tumors (n=40), borderline epithelial tumors (n ¼ 14), benign cystadenomas (n ¼ 28) and simple cysts (n ¼ 44) of the ovary. Premenopausal and postmenopausal subgroups were formed in each group. The concentration of FSH and LH was measured in serum and tumor fluid and the serum/tumor fluid ratio was calculated. The results in each group were compared and the sensitivity, specificity, positive and negative predictive values were determined.
Introduction
The stimulatory effect of gonadotropins on cell proliferation in vitro has been reported by many authors, prompting a search for the mechanisms involved (AbuJadweh et al. 1996 , Schiffenbauer et al. 1997 , Kuroda et al. 1998 , Hazelton et al. 1999 , Ohtani et al. 2001 . Among the various possibilities considered was the stimulation of angiogenesis mediated by the vascular endothelium growth factor (VEGF) (Schiffenbauer et al. 1997) . Attention was also focused on the role of gonadotropin-releasing hormones (GnRH).
The anti-proliferative activity of GnRH analogs in ovarian cancer appears to be well documented (Emons et al. 1993 , 1999 , Imai et al. 1994 , Kim et al. 1999 . Ovarian cancer cells are capable of producing gonadoliberin and possess a luteinizing hormone-releasing hormone (LHRH)-dependent system controlling cell proliferation (Ohno et al. 1993 , Kakar et al. 1994 , Emons et al. 2000 . Expression of LHRH has been confirmed in more than 90% of primary malignant epithelial tumors of the ovary. In addition, more than 80% of tumors carry receptors for this hormone (Ohno et al. 1993 , Imai et al. 1994 , Irmer et al. 1995 .
Studies on the expression of LHRH and its receptors in vitro have led to prospective trials using long-acting gonadoliberin analogs in ovarian cancer patients in whom therapeutic benefits were expected on the grounds of the gonadotropin theory of carcinogenesis (Lind et al. 1992 , Adelson et al. 1993 , Emons et al. 1996 , 1999 , Felberbaum et al. 2000 , Rzepka-Go´rska et al. 2002 . Although discord remains as to the interpretation of the results and some of the trials continue, partial remission or stabilization of the tumor was achieved in most cases (Lind et al. 1992 , Adelson et al. 1993 , Emons et al. 1996 , RzepkaGo´rska et al. 2002 . Nevertheless, lower than expected therapeutic efficacy of GnRH analogs motivated Kramer et al. (1998) to investigate gonadotropin concentrations in epithelial tumors of the ovary, pursuing the suggestion that tumor growth may depend rather on local than on serum concentrations of gonadotropins.
Continuing this line of research, we decided to compare follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations in serum and tumor fluid, as well as the serum/tumor fluid (S/F) ratio for both gonadotropins in malignant, borderline and benign epithelial tumors of the ovary.
Materials and methods
The study was performed in 126 patients treated at the Department of Gynecological Surgery and Oncology, Pomeranian Academy of Medicine in Szczecin, between May 1998 and August 2002. Four groups were formed depending on the histopathologic diagnosis: I, 40 patients with malignant epithelial tumors; II, 14 patients with borderline epithelial tumors; III, 28 patients with benign epithelial tumors; IV, 44 patients with serous cysts, follicular cysts, or paraovarian cysts of the ovary. Each group was divided into premenopausal and postmenopausal subgroups. Patient data are presented in Table 1 .
FSH and LH concentrations were measured in serum and tumor fluid using commercial MEIA test kits from Abbott and the AxSYM robotic analyzer. The sensitivity of the method for FSH and LH was 0.01 mIU/ml. Tumor fluid was obtained immediately after removal of the tumor from the true pelvis, with due care to avoid contamination with blood. Histopathologic diagnosis was established at the Department of Genetics and Pathomorphology, Pomeranian Academy of Medicine in Szczecin. The study protocol was approved by the local Bioethics Committee.
Statistics
Distribution of the results deviated from normal according to the Shapiro-Wilk W test. Consequently, means were compared using the non-parametric Kruskal-Wallis test for more than two variables and the Mann-Whitney U test for two variables. The level of significance was taken as P<0.05.
Application of cut-off limits permitted classification of the patients into four categories: true positive (a), true negative (b), false positive (c) and false negative (d). The sensitivity, specificity, positive and negative predictive values were calculated according to the following equations:
Positive predictive value ¼ ½a=ða þ cÞ Â 100
Negative predictive value ¼ ½b=ðb þ dÞ Â 100
Results
Mean concentrations of gonadotropins in each group are presented in Table 2 . Statistically significant differences in FSH and LH concentrations were revealed between malignant and benign ovarian tumor fluids. We also analyzed the diagnostic usefulness of mean gonadotropin Table 1 Patient data in postmenopausal women (M) and premenopausal woman (PM) with the total (W), with numbers in parentheses 
FIGO, international federation of gynecology and obstetrics.
concentrations in tumor fluid. Due to pre-and postmenopausal differences in gonadotropin concentrations, the patients were grouped accordingly. Mean gonadotropin concentrations in tumor fluid from pre-and postmenopausal patients of group I were taken as the cut-off levels ( Table 3) . The FSH S/F ratio was significantly lower in groups I and II as compared with III (Table 4) . The significance remained when the subgroups were compared. The difference between groups I and II was not significant and the same was true for pre-and postmenopausal subgroups. The LH S/F ratio was significantly lower in group I as compared with II. When postmenopausal women were compared, the ratio in group I remained lower but significance disappeared. The ratio was significantly lower in group I vs III and in the respective subgroups. No differences in the ratio were ascertained between groups II and III (Table 4 ).
The ratios in group IV were compared with the other three groups (Table 5 ). The FSH S/F ratio was significantly lower in groups I and II vs IV. Significance remained when pre-or postmenopausal women were compared. Lower values of this ratio in group III vs IV were revealed in postmenopausal women only. The LH S/F ratio was significantly lower in group I as compared with group IV, regardless of age. The ratio was lower in group II vs IV in all patients and in postmenopausal women. Only postmenopausal women of group III revealed a significantly lower ratio when compared with postmenopausal women of group IV.
The sensitivity, specificity, positive and negative predictive values are shown in Table 6 . Discussion Reimer et al. (1997) were the first to measure gonadotropin concentrations in tumor fluid. They compared gonadotropin concentrations in functional cysts with a heterogenic group of neoplastic cysts (serous and mucinous cystadenoma, cystadenofibroma, teratoma, borderline tumors and cystadenocarcinoma). Ovarian cyst fluid was obtained intraoperatively (laparoscopy or laparotomy) from 138 women in the pre-and postmenopausal period. No significant differences were detected between the two histological subgroups (functional and neoplastic cysts) in premenopausal patients. The number of postmenopausal women with functional cysts was insufficient to allow reliable comparisons regarding hormone levels. Nevertheless, these authors found very low postmenopausal FSH (0.45 IU/l) and LH (0.55 IU/l) concentrations in functional cysts and markedly higher levels in neoplastic cysts (FSH=10.2 IU/l; LH=2.4 IU/l). FSH and LH levels in serum and cyst fluid were also measured by Kramer et al. (1998) in 65 patients before and after menopause (20 with malignant epithelial tumors and 45 with benign epithelial tumors). Serum samples were obtained during surgery and cyst fluid was aspirated after surgical removal of the tumor. There were no significant differences in FSH and LH serum levels between patients with benign and malignant ovarian cysts. By contrast, FSH and LH levels in cyst fluid from patients with benign and malignant tumors were significantly different. While in ovarian cancer FSH and LH concentrations were high and nearly identical to the serum concentrations, gonadotropin concentrations in benign cysts were always below the measurement range of the assay. Unfortunately, Reimer et al. (1997) pooled epithelial tumors of varying malignancy and supplemented this group with germinal tumors (teratomas). Moreover, the number of postmenopausal women studied by these authors was not sufficient for statistical analysis. The findings of Kramer et al. (1998) appear very interesting. These authors reported significantly higher concentrations of FSH and LH in the fluid from malignant as compared with benign epithelial tumors of the ovary.
The present study was carried out in four groups of patients. We distinguished benign, borderline and malignant epithelial tumors and included a group of patients with functional ovarian cysts. Patients with histologically confirmed germinal tumors were excluded. Each group was large enough to permit reliable statistical comparison. Our classification according to three grades of malignancy of the ovarian tumors and comparison of the relevant patient groups may seem to be better founded.
In our opinion, FSH S/F and LH S/F are diagnostically more useful than the concentration of gonadotropins in the tumor fluid. We compared ovarian tumors of varying malignancy with cases of ovarian cysts. Significantly lower ratios were observed in pre-and postmenopausal women when tumor groups were pooled and compared with cysts. The FSH S/F ratio was lower in malignant and borderline cancer cases as compared with cysts in both pre-and postmenopausal women. When cystadenomas were compared with cysts, statistical significance was found for postmenopausal women only. The LH S/F ratio followed the same pattern. For pre-and postmenopausal women alike, both ratios were significantly lower in ovarian cancer as compared with borderline tumors and cystadenomas pooled together. FSH and LH S/F ratios appear diagnostically more useful. The ratio is independent of age, while gonadotropin concentration in tumor fluid is higher in post-than premenopausal women. Thus, gonadotropin concentrations require adjustment for age. In the case of the ratio, sensitivity is 78% for FSH and 72% for LH. In contrast, sensitivity was 40% for FSH and LH concentrations in premenopausal women, and 47% for FSH and 39% for LH in postmenopausal women.
We remain puzzled as to the cause of the high concentrations of gonadotropins in the fluid from malignant tumors. If one assumes that gonadotropins pass from serum to tumor fluid instead of being produced locally, the difficult question remains as to why levels are higher in malignant than benign tumors. Is gonadotropin transfer into tumor fluid more active in ovarian cancer?
What other mechanism can we envisage as long as production of gonadotropins by tumor cells remains an unconfirmed possibility?
Unlike the uncertainty as to the origin of high gonadotropin concentrations in the fluid from epithelial tumors of the ovary, sample evidence has been provided that gonadotropins support cell proliferation (Wimalsena et al. 1992 , Kurbacher et al. 1995 , Schiffenbauer et al. 1997 , Syed et al. 2001 through receptors expressed by tumor cells (Mandai et al. 1997 , Parrot et al. 2001 .
The studies performed by us and other researchers appear to be relevant to clinical practice. In our study, fluid was collected after removal of the ovarian tumor by laparotomy according to the standard oncologic procedure, mainly because approximately 75% of our patients were diagnosed with a neoplasm qualifying for surgery. Our findings may be helpful in the differentiation of malignant from benign tumors and thus appear to be clinically relevant. Diagnostic biopsy of minor cysts without ultrasonographic features of malignancy continues to be used (Petrovic et al. 2002 , Oleszczuk et al. 2002 , Modesit et al. 2003 . The risk of malignancy in unilocular ovarian cystic tumors of less than 10 cm in diameter is extremely low in women aged 50 or more (Modesitt et al. 2003) . Modesitt et al. (2003) examined 15 106 asymptomatic patients in order to determine the natural history and estimate the risk of malignancy of unilocular ovarian cystic tumors. Cytology of the ovarian tumor fluid is of limited diagnostic value and is subject to significant error (Dietrich et al. 1999 , Martinez-Onsurbe et al. 2001 . Therefore, hormonal tests could be of use during analysis of the tumor fluid. Biopsy of ovarian tumor can be recommended in specific cases. For example, it may be used as a therapeutic or diagnostic procedure in patients at high anesthesiologic risk (Petrovic et al. 2002) . Another specific group consists of patients with the BRCA1 or BRCA2 mutation (Go´rski et al. 2000) in whom the diagnosis and monitoring must be particularly scrupulous. Tumor biopsy may be an option in these patients as well.
In the light of the gonadotropin theory of ovarian tumorigenesis, gonadotropin patterns in patients with epithelial tumors of the ovary help substantiate the use of GnRH analogs and selective hormonal replacement therapy for the management of ovarian cancer. At the same time, the administration of high gonadotropin doses for induction of ovulation may not be an option in each case.
We have previously reported (Rzepka-Go´rska et al. 2002 that chemotherapy combined with radiotherapy and GnRH analogs offers the best results in ovarian cancer. Considering the findings of Schiffenbauer et al. (1997 Schiffenbauer et al. ( , 2002 ), it appears prudent to administer Endocrine-Related Cancer (2004) 11 315-321 www.endocrinology.org GnRH analogs during remission with the aim of lowering gonadotropin levels. This strategy would reduce the activity of VEGF, suppress cell adhesion, and prevent relapse and progression of the tumor. Additionally, it may be interesting to compare the results in women with or without expression of FSH, LH and LHRH receptors by the tumor.
Our findings provide evidence for the involvement of gonadotropins in carcinogenesis. Determination of the gonadotropin S/F ratio may be helpful in the differential diagnosis of ovarian tumors.
